A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Male and Female Volunteers Without Childbearing Potential
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2014
At a glance
- Drugs AZD 2423 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 Dec 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 09 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 New trial record